876617-25-3

Usage

Uses

Used in Pharmaceutical Synthesis:
(R)-1-BOC-3-FLUORO PYRROLIDINE is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of complex molecular structures. The BOC protecting group ensures that the amine functionality remains protected during the synthesis process, allowing for selective reactions to occur elsewhere in the molecule.
Used in Fine Chemical Production:
In the production of fine chemicals, (R)-1-BOC-3-FLUORO PYRROLIDINE serves as a key building block, leveraging its unique structural features to create specialized compounds with tailored properties. The fluorine atom in the compound can influence reactivity and stability, making it a valuable component in the synthesis of high-value chemical products.
Used in Organic Synthesis:
(R)-1-BOC-3-FLUORO PYRROLIDINE is utilized as a versatile reagent in organic synthesis, where its protected amine and fluorinated pyrrolidine ring can be incorporated into a wide range of organic compounds. (R)-1-BOC-3-FLUORO PYRROLIDINE's properties make it suitable for use in the creation of novel molecules with potential applications in various industries, including materials science, agrochemicals, and specialty chemicals.

InChI:InChI=1/C9H16FNO2/c1-9(2,3)13-8(12)11-5-4-7(10)6-11/h7H,4-6H2,1-3H3/t7-/m1/s1

Upstream product

• 371240-55-0 (S)-3-(toluene-4-sulfonyloxy)pyrrolidin-1-ylcarboxylic acid tert-butyl ester 
• 101469-92-5 (S)-3-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 136725-53-6 (3R)-3-fluoropyrrolidine hydrochloride 

Relevant academic research and scientific papers

Halogen-substituted latrotinib compound

The invention relates to a halogen-substituted latrotinib compound. The halogen-substituted latrotinib compound comprises a latrotinib bisulfate compound labeled by a radioactive halogen atom or a non-radioactive halogen atom. The compound comprises a (R,

OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES

The present invention discloses novel aryl oxazole compounds of Formula I (I), or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing and using such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. Formula I (I) or a pharmaceutically acceptable salt thereof, wherein: m is independenlly at each occurrence 1, 2, or 3, Z independently represents carbon (substituted with hydrogen or the optional substituents indicated herein) or nitrogen, provided that when Z is nitrogen then R6 is not attached to Z; R1 and R2 are independently -(C1-C7) alkyl(optionally substituted with one to three halogens), or R1 and R2 and the nitrogen to which they are attached form an azetidinyl ring, a pyrrolidinyl ring, or a piperidinyl ring, wherein further the azetidinyl, pyrrolidinyl, or piperidinyl ring so formed may be optionally substituted one to three times with R5; R6 is independently at each occurrence -H, -halogen, or -CH3.

2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF

The invention relates to pyrrolo pyrimidines of formula (I), wherein Y represents -(CH2)t-O- or -(CH2)r-S-, p is 1 or 2, r is 1, 2 or 3, t is 1, 2 or 3, or Y is -(CH2)j- or -CH=CH-, j is 1 or 2; p is 1 or 2, or Y is -(CH2)f-, f is 1 or 2, p is 1, and the further radicals and symbols have the meaning as defined herein; their preparation, their use as pharmaceuticals, pharmaceutical compositions containing them, the use of such a compound for the manufacture of a pharmaceutical preparation for the treatment of neuropathic pain and to a method for the treatment of such a disease in animals, especially in humans.